GPN Vaccines Secures $10 Million for Pneumococcal Vaccine Progress

GPN Vaccines, a biotechnology firm specializing in the development of bacterial vaccines, has announced the successful closure of a $10 million private funding round, with participation from both new and returning investors. This funding will facilitate the ongoing development of the company’s lead candidate, Gamma-PN, as it moves towards Phase 2 clinical trials.

Funding Utilization Goals

The newly acquired capital will be instrumental in several key development initiatives. These include the production of Good Manufacturing Practice (cGMP) compliant batches, enhancing the company's opsonophagocytic activity (OPA) testing laboratory capabilities, and the preparation of an Investigational New Drug application for the FDA.

Understanding Gamma-PN

The Gamma-PN vaccine is specifically engineered to offer broad immunity against Streptococcus pneumoniae, the bacterium that leads to pneumococcal infections. Traditionally, vaccines have targeted only a subset of the more than 100 known serotypes of this bacterium.

GPN Vaccines is innovating by focusing on protein antigens that are shared across various pneumococcal strains. This groundbreaking strategy could potentially allow for broader immunity against both existing and future serotypes without the need to include each one in the vaccine mixture.

Clinical Trial Advances

So far, GPN Vaccines has successfully conducted four Phase 1 studies to assess the safety and immunogenicity of Gamma-PN across diverse adult populations. The results demonstrated promising functional OPA antibody responses, showcasing the vaccine's ability to target multiple serotypes effectively.

A forthcoming clinical study is set to be a multinational, randomized, double-blinded trial that will test a single dose of Gamma-PN in participants aged 50 and older.

Market Potential

The global market for pneumococcal vaccines is substantial, exceeding $9 billion per year, notably with established products from major companies like Pfizer and Merck.

In addition to the Gamma-PN project, GPN Vaccines is also developing a range of vaccine programs that target other bacterial threats such as Streptococcus suis, non-typeable Haemophilus influenzae, and Moraxella catarrhalis.

Expert Insights

“For decades, pneumococcal vaccine development has focused on expanding the number of serotypes included in increasingly complex products. Gamma-PN is designed to take a fundamentally different approach by targeting protein antigens inherent to all pneumococcal strains, with the goal of providing broad protection regardless of serotype. This financing provides the resources to complete key Phase 2-enabling activities and advance a program that we believe could meaningfully expand the possibilities for pneumococcal disease prevention. We are grateful to our existing and new investors for their confidence in our vision.”

Tim Hirst, Ph.D., Chairman And CEO Of GPN Vaccines

“The size of the pneumococcal vaccine market reflects both the enormous global disease burden and the value of effective vaccination, yet the industry is still constrained by vaccines that address serotypes individually. Gamma-PN takes a fundamentally different approach. By targeting protein antigens common across pneumococcal strains, it is designed to generate functional immunity broadly across serotypes without requiring each one to be incorporated into the vaccine. As such, we believe Gamma-PN has the potential to upend the current serotype-specific model in a market where the leading vaccine franchise generates approximately $6.5 billion in annual sales.”

Bruce Forrest, M.D., Ph.D., MBA, Executive Chief Scientific Officer Of GPN Vaccines